A Study of Imlifidase in Patients With Guillain-Barré Syndrome

Summary

The study participants are patients which have been diagnosed with Guillain-Barré Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of care treatment for GBS patients. The patients in this study will be treated with the study medicine imlifidase on day 1, and with IVIg on days 3-7. The purpose of this study is to investigate the safety and effectiveness of imlifidase in patients diagnosed with GBS.

Timeline

Start

2019-11-12

Primary completion

2024-02-27

Completion

2024-02-27

Drugs

Indications